Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung Cancer

Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung Cancer

Background and objective Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that selectively binds to and neutralizes the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) in October 2006 for use...

Full description

Bibliographic Details
Main Authors: Wei WU, Liyan XU, Zhe LIU, Yunzhong ZHU, Heling SHI, Junfang TANG, Zan LIU, Qiyi MENG, Lili GUO, Hong TAO, Mingzhi LI
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2009-03-01
Series:Chinese Journal of Lung Cancer
Subjects:
Bevacizumab
Lung neoplasms
Safety
Online Access:http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2009.03.006&path%5B%5D=250

Similar Items

Similar Items